Keyphrases
Additional Therapy
10%
Alternative Anticoagulants
10%
Antibody Binding
10%
Antibody-mediated
10%
Anticoagulant Therapy
10%
Antigen Binding
10%
Bleeding Risk
10%
Common Polymorphism
10%
Constant Domain
10%
Direct Oral Anticoagulants
10%
Disease Course
10%
Enzyme-linked Immunosorbent Assay (ELISA)
10%
Genotype
20%
Heparin-induced Thrombocytopenia
100%
High Dose
10%
IgG Fc
10%
IgG Receptors
10%
Immediate Response
10%
Immunoassay
10%
Induced Activation
10%
Intravenous Immunoglobulin (IVIg)
100%
Long-term Anticoagulation
10%
Mechanism of Action
10%
Patient Demographics
10%
Platelet Activation
20%
Platelet Factor 4
10%
Platelets
30%
Polymorphism
10%
Severe Disease
10%
Severe Thrombocytopenia
10%
Severely Affected
10%
Solid Phase
10%
Sustained Response
10%
Thrombocytopenia
10%
Thromboembolism
10%
Thrombosis
10%
Treatment Challenges
10%
Biochemistry, Genetics and Molecular Biology
Anticoagulation
12%
Antigen Binding
12%
Drug Megadose
12%
Enzyme
12%
Genotyping
12%
Heparin-Induced Thrombocytopenia
100%
Immunoassay
25%
Platelet
37%
Platelet Factor 4
12%
Solid
12%
Thrombocyte Activation
25%
Thrombocytopenia
25%
Immunology and Microbiology
Anticoagulation
12%
Binding Antibody
25%
Drug Megadose
12%
Heparin Induced Thrombocytopenia
100%
Immunoassay
25%
Immunology
25%
Platelet
37%
Platelet Factor 4
12%
Solid
12%
Thrombocyte Activation
25%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
12%
Anticoagulation Therapy
12%
Direct Oral Anticoagulant
12%
Disease
12%
Disease Course
12%
Heparin Induced Thrombocytopenia
100%
Immunoassay
25%
Receptor
12%
Refractory Thrombocytopenia
12%
Thrombocyte Factor 4
12%
Thrombocytopenia
12%
Thromboembolism
12%
Thrombosis
12%